Apixaban 5 MG + Apixaban 2.5 MG + Warfarin
Phase 3Terminated 3 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Aortic Valve Disease
Conditions
Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure
Trial Timeline
May 1, 2020 → Dec 12, 2022
NCT ID
NCT04142658About Apixaban 5 MG + Apixaban 2.5 MG + Warfarin
Apixaban 5 MG + Apixaban 2.5 MG + Warfarin is a phase 3 stage product being developed by Artivion for Aortic Valve Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04142658. Target conditions include Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure.
What happened to similar drugs?
6 of 13 similar drugs in Aortic Valve Disease were approved
Approved (6) Terminated (3) Active (6)
Hype Score Breakdown
Clinical
17
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04142658 | Phase 3 | Terminated |
Competing Products
20 competing products in Aortic Valve Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edoxaban | Daiichi Sankyo | Phase 3 | 36 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 43 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 35 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 40 |
| candesartan + placebo | AstraZeneca | Phase 3 | 36 |
| Sugammadex | Merck | Approved | 43 |
| bisoprolol + placebo | Merck | Approved | 35 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 42 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 42 |
| fluvastatin | Novartis | Phase 2 | 31 |
| ACZ885 + Placebo | Novartis | Phase 2 | 27 |
| Evolocumab + Placebo | Amgen | Phase 1 | 36 |
| atorvastatin (Lipitor) | Pfizer | Approved | 35 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 40 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 29 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 35 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 35 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 29 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 37 |
| Desflurane | Baxter | Approved | 36 |